Calliditas Therapeutics AB

CALTX

Equity

ISIN SE0010441584 / Valor 42290712

NASDAQ Nordic Exchange Stockholm, Equities (2024-09-18)

SEK 206.20%

Calliditas Therapeutics AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Calliditas Therapeutics AB, founded in 2004 and originally named Pharmalink AB, is a Swedish biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases. The company focuses on addressing unmet medical needs, particularly in the area of renal and hepatic diseases. Calliditas' lead product, Nefecon, is an oral formulation designed to treat primary IgA nephropathy, a rare kidney disorder. The company leverages its expertise in formulation sciences, product development, and regulatory affairs to advance its pipeline of innovative therapies. With a team of experienced professionals from various leading pharmaceutical companies, Calliditas aims to bring effective treatments to market, improving the lives of patients with rare and serious conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Q4 2023 Revenue Growth

In the fourth quarter of 2023, Calliditas Therapeutics AB reported a significant increase in revenue, totaling SEK 451.6 million, compared to SEK 429.0 million in the same quarter of the previous year. This growth was primarily driven by the net sales of TARPEYO, which surged to SEK 347.3 million (USD 32.6 million) from SEK 167.3 million (USD 16.1 million) in Q4 2022, marking a 108% increase year-over-year.

Q4 2023 Operating Performance

Calliditas Therapeutics AB's operating expenses in Q4 2023 were stable at SEK 387.5 million, slightly down from SEK 388.7 million in Q4 2022. The operating income for the quarter improved to SEK 41.8 million from SEK 32.5 million in the previous year, reflecting better operational efficiency and revenue growth.

Q4 2023 Cash Flow and Cash Position

The cash flow from operating activities for Calliditas Therapeutics AB in Q4 2023 was SEK 22.8 million (approximately USD 2.2 million), a decrease from SEK 230.0 million in Q4 2022. The company's cash position at the end of December 2023 was SEK 973.7 million (approximately USD 93.6 million), down from SEK 1,249.1 million at the end of December 2022.

2024 Financial Outlook

Calliditas Therapeutics AB has projected its total net sales for the year ending December 31, 2024, to be in the range of USD 150-180 million. This forecast reflects the company's expectations for continued growth, driven by the expanded use and market acceptance of TARPEYO following its full approval in the US.

Key Financial Highlights of Q4 2023

Calliditas Therapeutics AB achieved several key financial milestones in Q4 2023, including a record increase in TARPEYO sales and a robust enrollment growth. The company also maintained a strong cash position, which supports its ongoing operations and strategic initiatives aimed at expanding its market presence and enhancing its product offerings in the nephrology sector.

Summarized from source with an LLMView Source

Key figures

121%1Y

109%3Y

297%5Y

Performance

71.1%1Y

71.6%3Y

64.8%5Y

Volatility